Fulcrum Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Cadavid Diego | SVP Clinical Development | Option Exercise | 338 | $4.83 | $1,633 | 67,123 | Jun 2, 2020 |
| Gould Robert J | See Remarks | Sale | 2,797 | $20.00 | $55,940 | 546,234 | Jun 1, 2020 |
| Gould Robert J | See Remarks | Sale | 1,919 | $20.01 | $38,399 | 550,426 | May 29, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Sale | 2,232 | $20.00 | $44,640 | 127,088 | May 28, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 200 | $20.04 | $4,008 | 66,785 | May 28, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Option Exercise | 448 | $7.84 | $3,512 | 127,536 | May 27, 2020 |
| Gould Robert J | See Remarks | Sale | 2,500 | $20.00 | $50,000 | 552,345 | May 26, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Option Exercise | 412 | $7.84 | $3,230 | 127,500 | May 26, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 1,860 | $18.00 | $33,480 | 66,785 | May 12, 2020 |
| Thomson Peter G. | VP Finance & Accounting | Sale | 7,500 | $16.00 | $120,000 | 21,071 | May 11, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 315 | $18.13 | $5,711 | 66,785 | Mar 2, 2020 |
| Thomson Peter G. | VP Finance & Accounting | Sale | 2,102 | $17.43 | $36,638 | 28,821 | Feb 24, 2020 |
| Gould Robert J | See Remarks | Sale | 2,500 | $20.00 | $50,000 | 554,845 | Feb 19, 2020 |
| Wallace Owen B. | Chief Scientific Officer | Sale | 6,088 | $20.00 | $121,760 | 127,088 | Feb 19, 2020 |
| Cadavid Diego | SVP Clinical Development | Sale | 2,143 | $17.33 | $37,138 | 68,928 | Feb 3, 2020 |
| Thomson Peter G. | VP Finance & Accounting | Sale | 4,738 | $17.17 | $81,351 | 33,833 | Jan 23, 2020 |
| Section 32 Fund 2, LP | — | C | 464,285 | — | — | 464,285 | Jul 22, 2019 |
| LEVIN MARK J | — | Purchase | 81,250 | $16.00 | $1,300,000 | 5,962,202 | Jul 22, 2019 |
| Casdin Partners Master Fund, L.P. | — | C | 464,285 | — | — | 464,285 | Jul 22, 2019 |
| 6 Dimensions Capital, L.P. | — | Purchase | 118,750 | $16.00 | $1,900,000 | 559,821 | Jul 22, 2019 |
| STARR KEVIN P | — | C | 5,595,238 | — | — | 5,880,952 | Jul 22, 2019 |
| Third Rock Ventures GP IV, L.P. | — | C | 2,261,904 | — | — | 2,261,904 | Jul 22, 2019 |
| Sanofi | — | Purchase | 93,750 | $16.00 | $1,500,000 | 558,035 | Jul 22, 2019 |
| GLAXOSMITHKLINE PLC | — | C | 1,785,714 | — | — | 1,785,714 | Jul 22, 2019 |